Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

Eli Lilly's mevidalen, a dopamine D1 receptor modulator, failed to meaningfully improve cognition or daily function in the phase 2 PRESENCE-ALZ trial. The drug's posterior probabilities for benefit fell well short of the required threshold, and only one secondary measure showed any nominal improvement — casting doubt on the D1 dopamine pathway as a viable treatment target in Alzheimer's disease.
Eli Lilly's Alzheimer's drug mevidalen stumbles in phase 2 trial. Eli Lilly's mevidalen — an investigational dopamine D1 receptor (D1R) positive allosteric modulator — failed to clear the primary efficacy bar in PRESENCE-ALZ, a phase 2 trial enrolling 304 adults with mild-to-moderate Alzheimer's disease (AD). Participants were randomized to placebo, mevidalen 25 mg, or mevidalen 50 mg once daily for 24 weeks.
The trial's Bayesian primary analysis required a greater than 60% posterior probability that either dose would produce at least a 2-point benefit on the Integrated Alzheimer's Disease Rating Scale (iADRS). Instead, probabilities came in at just 14.0% (25 mg) and 21.2% (50 mg). Across a broad sweep of secondary endpoints — covering cognition, function, global impression, and neuropsychiatric symptoms — only one measure, the Quick Dementia Rating System, showed a nominally significant edge for the 50 mg dose. This follows a similar outcome in Lewy body dementia, where mevidalen also missed its primary cognitive endpoint, raising serious questions about whether boosting D1-mediated dopamine signaling translates into meaningful clinical benefit.
By the Numbers:
Why it matters: With Alzheimer's drug development remaining notoriously difficult, this back-to-back failure across two neurodegenerative conditions suggests the D1 dopamine potentiation strategy may not deliver the cognitive gains researchers had hoped for — narrowing the field of viable therapeutic approaches.